Table 4.
Ongoing and upcoming clinical trials investigating combination therapies in HCC.
| Trial Name, Number | Phase | a-PD-1/PD-L1 | Combined Therapy | Estimated Sample Size | Status | Primary Outcome Measures |
|---|---|---|---|---|---|---|
| NCT04829383 | II | Atezolizumab | Bevacizumab (VEGF- targeting) | 50 | Recruiting | Frequency and severity of toxicities |
| NCT04770896 | II | Atezolizumab | Lenvatinib (TKI) | 554 | Recruiting | OS |
| NCT04826406 | III | Camrelizumab | Apatinib (TKI) | 40 | Recruiting | ORR |
| NCT04443309 | I/II | Camrelizumab | Lenvatinib (TKI) | 53 | Recruiting | ORR |
| NCT05048017 | II | Camrelizumab | Regorafenib (TKI) | 20 | Recruiting | PFS |
| NCT04806243 | II | Camrelizumab | Regorafenib (TKI) | 69 | Recruiting | OS |
| NCT04310709 | II | Nivolumab | Regorafenib (TKI) | 42 | Recruiting | ORR |
| NCT04170556 | I/II | Nivolumab | Regorafenib (TKI) | 78 | Recruiting | Rate of AE, related AEs, death |
| CheckMate 9DW NCT04039607 |
III | Nivolumab | Ipilimumab (CTLA-4-targeting) | 728 | Recruiting | OS |
| NCT05199285 | II | Nivolumab | Ipilimumab (CTLA-4-targeting) | 40 | Not yet recruiting | ORR |
| NCT05096715 | 1B | Atezolizumab | Bevacizumab (VEGF targeting) + stereotactic beam radiation therapy | 20 | Not yet recruiting | Dose limiting toxicity Rate |
| NCT03482102 | II | Durvalumab | Tremelimumab (CTLA-4-targeting) + radiation therapy | 70 | Recruiting | BOR |
| NCT05488522 | I | Atezolizumab | Bevacizumab (VEGF targeting) + stereotactic beam radiation therapy |
OS, Overall Survival; BOR, Best Overall Response.